Decheng affiliates reduce BYSI stake by 13,876 shares over three days
Rhea-AI Filing Summary
Decheng Capital affiliates and Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares across three trading dates. Fund III sold 7,507 shares on 10/08/2025 at a weighted average price of $1.77, 3,979 shares on 10/09/2025 at a weighted average price of $1.81, and 2,390 shares on 10/10/2025 at a weighted average price of $1.77, totaling 13,876 shares sold. After these transactions, Fund III reports beneficial ownership of 1,804,020 shares. Related Decheng entities report additional indirect holdings of 1,617,409 and 891,734 shares respectively, held by Fund II and the Global Healthcare master fund. The filing discloses that reported prices are weighted averages across specified price ranges and that general partners and Dr. Cui may be deemed to beneficially own the funds' holdings while disclaiming direct ownership beyond pecuniary interest.
Positive
- Maintained substantial indirect holdings: Fund III still holds 1,804,020 shares after sales
- Transparent pricing disclosure: Weighted average prices and price ranges were disclosed for the sales
Negative
- Insider selling activity: 13,876 shares sold across three days, reducing insider-held float
- Concentrated related-party ownership: Multiple Decheng funds combined hold > 3.3M shares indirectly, concentrating exposure
Insights
TL;DR: Multiple sales by affiliated funds reduced indirect holdings by 13,876 shares over three days.
The transactions show coordinated disposition by Decheng Capital China Life Sciences USD Fund III, L.P. across 10/08/2025–10/10/2025, with weighted average sale prices reported at $1.77 and $1.81. The filing documents remaining indirect holdings of 1,804,020 shares for Fund III and material additional indirect positions in related funds, indicating sustained, multi-entity exposure to the issuer.
Key dependencies include the stated weighted-average pricing ranges and the relationships between funds, GPs, and Dr. Cui. Monitor short-term trading volumes and subsequent Form 4 filings for further changes; near-term disclosure windows (weeks) typically reveal whether these sales continue or cease.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 2,390 | $1.77 | $4K |
| Sale | Ordinary Shares | 3,979 | $1.81 | $7K |
| Sale | Ordinary Shares | 7,507 | $1.77 | $13K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.805 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
